Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone610-640-4202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$52.78 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date6/4/2019 (Estimated)
OptionableNot Optionable
Neuronetics (NASDAQ:STIM) Frequently Asked Questions
What is Neuronetics' stock symbol?
Neuronetics trades on the NASDAQ under the ticker symbol "STIM."
How were Neuronetics' earnings last quarter?
Neuronetics Inc (NASDAQ:STIM) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.01. View Neuronetics' Earnings History.
When is Neuronetics' next earnings date?
What guidance has Neuronetics issued on next quarter's earnings?
Neuronetics issued an update on its first quarter 2019 earnings guidance on Tuesday, March, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $12.4-13 million, compared to the consensus revenue estimate of $13.01 million.Neuronetics also updated its FY 2019 guidance to EPS.
What price target have analysts set for STIM?
5 equities research analysts have issued 12 month target prices for Neuronetics' shares. Their predictions range from $25.00 to $40.00. On average, they anticipate Neuronetics' share price to reach $32.25 in the next year. This suggests a possible upside of 122.4% from the stock's current price. View Analyst Price Targets for Neuronetics.
What is the consensus analysts' recommendation for Neuronetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neuronetics.
What are Wall Street analysts saying about Neuronetics stock?
Here are some recent quotes from research analysts about Neuronetics stock:
- 1. BTIG Research analysts commented, "$25 PT Neuronetics reported 4Q18 results with both capital sales and treatment revenue surpassing our forecast. Ending BDM count was in-line with expectations, implying rep productivity is ahead of planned (mgmt confirmed the same). Looking ahead to FY19, top-line guidance brackets current Street estimates. Mgmt is assuming more rep hires than the Street, driving up the operating expense outlook. On underlying assumptions, mgmt appears to be basing forecasts on historical productivity metrics instead of more recent encouraging trends likely creating upside. Additionally, the company does not appear to be aggressively signaling gross margin expansion though we still feel a greater mix of higher-margin consumable sales should push this metric higher." (3/6/2019)
- 2. According to Zacks Investment Research, "Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. " (11/10/2018)
Has Neuronetics been receiving favorable news coverage?
News stories about STIM stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neuronetics earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Neuronetics' key competitors?
Some companies that are related to Neuronetics include K2M Group (KTWO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), Axonics Modulation Technologies (AXNX), OraSure Technologies (OSUR), Orthopediatrics (KIDS), LeMaitre Vascular (LMAT), SurModics (SRDX) and Antares Pharma (ATRS).
What other stocks do shareholders of Neuronetics own?
Who are Neuronetics' key executives?
Neuronetics' management team includes the folowing people:
- Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
- Mr. Peter L. Donato, VP of Fin. & CFO (Age 49)
- Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
- Mr. Stephen MacKinnon, VP of Sales
- Ms. Cassie Hallberg, VP of Marketing
When did Neuronetics IPO?
(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
Who are Neuronetics' major shareholders?
Neuronetics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.48%), Lord Abbett & CO. LLC (2.43%), FMR LLC (1.28%), RTW Investments LP (0.95%), Bellevue Group AG (0.94%) and United Services Automobile Association (0.44%). Company insiders that own Neuronetics stock include Daniel Guthrie, Peter Donato and Wilfred E Jaeger. View Institutional Ownership Trends for Neuronetics.
Which institutional investors are selling Neuronetics stock?
Which institutional investors are buying Neuronetics stock?
STIM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bellevue Group AG, Partner Fund Management L.P., United Services Automobile Association, Millennium Management LLC, Virtus ETF Advisers LLC, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Neuronetics stock in the last two years include Daniel Guthrie and Wilfred E Jaeger. View Insider Buying and Selling for Neuronetics.
How do I buy shares of Neuronetics?
Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuronetics' stock price today?
One share of STIM stock can currently be purchased for approximately $14.50.
How big of a company is Neuronetics?
Neuronetics has a market capitalization of $261.80 million and generates $52.78 million in revenue each year. The company earns $-24,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis.
What is Neuronetics' official website?
How can I contact Neuronetics?
Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]
MarketBeat Community Rating for Neuronetics (NASDAQ STIM)
MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote "Outperform" if you believe STIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
